Incidence of second tumors after treatment with or without radiation for rectal cancer

Rombouts, Anouk J. M.; Hugen, Niek; Elferink, M.A.G.; Feuth, Ton; Poortmans, Philip; Nagtegaal, Irıs D.; Wilt, Johannes H. W. de

doi:10.1093/annonc/mdw661

Cited by 31 publications

(36 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was the first large Asian general population-based study, which is in concordance with the results of a previous SEER data-based study [11] or previous Netherlands population-based cancer registry [13]. Competing risk regression model adjusted for death was used in our study to show a decreasing risk of prostate cancer after radiation therapy, compared with no radiation therapy in the rectal cancer patients group.…”

Section: Discussionsupporting

confidence: 85%

“…Although the results showed that the potential prostate cancer risk from radiotherapy was small [10], a long-term risk in rectal cancer survivors should not be overlooked. In last year, two articles related to this topic were published, all with the same results of protection of prostate cancer incidence [12,13]. In this study, we recruited a nationally representative cohort of rectal cancer patients to investigate whether rectal cancer patients who received radiotherapy are at a greater risk of prostate cancer after a maximum of 13 years of follow-up.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Population-Based Study of Secondary Prostate Cancer Risk after Radiotherapy in Male Patients with Rectal Cancer: A Retrospective Cohort Study

Chuang

Lee

et al. 2019

Medicina

View full text Add to dashboard Cite

Background and objective: Risk of secondary prostate cancer after radiation therapy among patients with rectal cancer remains undetermined. Given an increased incidence of rectal cancer in younger people and improved survival for rectal cancer patients who received radiation therapy, the potential risk of secondary prostate cancer needs to be further investigated. Materials and Methods: Male patients (n = 11,367) newly diagnosed rectal cancer and who underwent abdominoperineal resection (APR) or low anterior resection (LAR) from 1 January, 1998 to 31 December, 2010 were identified from Taiwan National Health Insurance Research Database. The incidence and relative risk of secondary prostate cancer in study patients with (n = 1586) and without (n = 9781) radiotherapy within one year after rectal cancer diagnosis were compared using a competing-risks analysis. Results: Rectal cancer patients with radiotherapy were at a significantly decreased risk of developing prostate cancer, with a hazard ratio (HR) of 0.41 (95% confidence interval = 0.20–0.83) after adjustment for age. Analysis of the risk estimated for various follow-up lengths suggested that a decreasing HR was seen through the period followed-up and that there was a trend of decreasing prostate cancer risk with time after radiotherapy. Conclusions: Radiotherapy was significantly associated with decreased risk of secondary prostate cancer among rectal cancer patients, by a magnitude of 59%.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Introductionmentioning

confidence: 99%

A Population-Based Study of Secondary Prostate Cancer Risk after Radiotherapy in Male Patients with Rectal Cancer: A Retrospective Cohort Study

Chuang

Lee

et al. 2019

Medicina

View full text Add to dashboard Cite

show abstract

“…The reduction of prostate cancers was confirmed in other studies, but they also found an increased risk for some gynaecological cancers. [214][215][216] The latter study, also found an increased risk for lung cancer and lymphoma in irradiated patients. 216 Effect on distant failure?…”

Section: Toxicity From Radiotherapymentioning

confidence: 73%

Tumour regression after radiotherapy for rectal cancer – Results from the randomised Stockholm III trial

Erlandsson

Lörinc

Ahlberg

et al. 2019

Radiotherapy and Oncology

112

View full text Add to dashboard Cite

“…Our proposed nomogram could be useful for calculating the 3‐year, 5‐year, and 10‐year probabilities of developing an SPM in the presence of competing causes of death. Unlike most prior studies that have assessed the overall risk of developing an SPM among cancer survivors from an overall perspective , our study focused on the prediction from a more accurate perspective. Patients’ risk of SPMs can be estimated if their characteristics are given.…”

Section: Discussionmentioning

confidence: 99%

Second Primary Malignancies in Patients with Colorectal Cancer: A Population-Based Analysis

Jia

Yuan

et al. 2020

The Oncologist

View full text Add to dashboard Cite

Purpose. This study aimed to profile the characteristics of patients with colorectal cancer (CRC) with a second primary malignancy (SPM) and to identify patients with CRC at high risk of developing SPMs. Methods. We retrospectively reviewed data on patients with CRC aged 20-79 years from the Surveillance, Epidemiology, and End Results (SEER) database. Eligible patients were categorized into only one primary malignancy and SPM cohorts. A competing-risk model was used to quantify associations between SPM occurrence and the multiple traits of patients. Finally, a decision curve analysis (DCA) was used to evaluate the clinical usefulness of the model by calculating net benefit. Results. A total of 179,884 patients were identified, 18,285 (10.2%) of whom developed SPMs during a maximum followup of approximately 18 years. The median survival time after the second diagnosis was less than 4 years. The 3-year, 5-year, and 10-year cumulative risks of developing an SPM were 3.9%, 5.9%, and 10.0%, respectively. According to the multivariable competing-risk model, male colon cancer survivors, older in age, with a well-differentiated tumor and localized disease, who were treated with surgery were susceptible to SPMs. The DCA yielded a wide range of risk thresholds at which the net benefits would be obtained from our proposed model. Conclusion. CRC survivors remain at high risk of developing SPMs. Patients with a second diagnosis of cancer showed not only significantly worse survival but also higher cancerspecific mortality. A web-based individualized predictive tool was also provided to assist clinicians in identifying patients at high risk of developing SPMs and planning their future care management. The Oncologist 2020;25:e651-e658 Implications for Practice: Colorectal cancer survivors remain at high risk of developing a second primary malignancy (SPM). This study aimed to profile the characteristics of patients with colorectal cancer with second primary malignancies and to further explore the risk factors related to the development of second primary malignancies, using a large population-based cohort. A clinically useful competing-risk nomogram was developed to predict the risk of SPMs based on individual clinical factors. According to the findings, older age, male sex, white or black race, localized disease, and treatment with surgery among patients with colon cancer were associated with an increased risk of developing an SPM. These findings and the proposed tool could be useful to clinicians and caregivers in the clinical counseling of patients with colorectal cancer and the development of long-term care management. 145,600 new patients with CRC in 2019 [1]. With the advancements in cancer treatment, increased early-stage Correspondence: Zhenyu Wu, Ph.D.,

show abstract

Incidence of second tumors after treatment with or without radiation for rectal cancer

Cited by 31 publications

References 25 publications

A Population-Based Study of Secondary Prostate Cancer Risk after Radiotherapy in Male Patients with Rectal Cancer: A Retrospective Cohort Study

A Population-Based Study of Secondary Prostate Cancer Risk after Radiotherapy in Male Patients with Rectal Cancer: A Retrospective Cohort Study

Tumour regression after radiotherapy for rectal cancer – Results from the randomised Stockholm III trial

Second Primary Malignancies in Patients with Colorectal Cancer: A Population-Based Analysis

Contact Info

Product

Resources

About